Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-06-02 Bisphosphonates and other drugs affecting bone metabolism
| Burosumab Crysvita® |
|
Formulary
|
Burosumab is recommended, within its marketing authorisation, as an option for treating X‑linked hypophosphataemia (XLH) in adults. |
 NICE TA993: Burosumab for treating X-linked hypophosphataemia in adults |
|
| Romosozumab Evenity® |
|
Formulary
|
Solution for injection in pre-filled pen 105mg |
|
NICE TA791: Romosozumab for treating severe osteoporosis |
|
|
Links
LSCMMG: Denosumab as a second line treatment option for the prevention of osteoporotic fragility fractures position statement- LSCMMG: Ibandronic acid tablets
- LSCMMG: Shared care guideline (Denosumab 120mg injection (Xgeva®))
- LSCMMG: Shared care guideline (Denosumab 60mg injection (Prolia®))
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA Drug Safety Update Aug 2020: Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment
- MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal
- MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal
- MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate
- MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation
- MHRA Drug Safety Update May 2022: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia
- MHRA safety update Dec 2014:Rare cases of atypical femoral fracture with long-term use
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: atypical femoral fractures
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: osteonecrosis of the jaw
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
- MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
- MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
- MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
- MHRA: Denosumab: updated recommendations
- MHRA: Denosumab: updated recommendations
- MHRA: Strontium: cardiovascular risk—restricted indication and new monitoring requirements
- NICE TA204: Osteoporotic fractures - denosumab
- NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
- NICE TA464: Bisphosphonates for treating osteoporosis
- NICE TA791: Romosozumab for treating severe osteoporosis
- NICE TA993: Burosumab for treating X-linked hypophosphataemia in adults
- Osteoporosis Guideline (NOGG 2021)